Pyrotinib

DB14993InvestigationalSmall molecule

Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2 and Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₃₂H₃₁ClN₆O₃ · 583.09 g/mol (avg)
Code names: SHR-1258

Resolves to

Compound

Structure

InChIKeySADXACCFNXBCFY-IYNHSRRRSA-NSMILESCCOC1=C(NC(=O)\C=C\[C@H]2CCCN2C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(OCC2=NC=CC=C2)C(Cl)=C1

Targets

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

158Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pyrotinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.